EUCTR2008-004541-29-FR进行中（未招募）不适用
A phase II Study of Azacitidine (Vidaza®) combined to Epoetin beta (NeoRecormon®) in IPSS low-risk and intermediate-1 MDS Patients, resistant to ESA - GFM-Aza-Epo-2008-01
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •MDS defined as
- •RCMD, RA with or without ring sideroblasts
- •RAEB 1, or CMML 1, if WBC < 13 G /l according to the WHO classification (see appendix 1)
- •with a low or int-1 IPSS score
- •primary or secondary resistance to epoetin alpha/ beta (> 60000 U/w) or darbepoetin (> 300ug/w), administered for at least 12 weeks
- •requirement of RBC transfusions > 4 U in the previous 8 weeks
- •Aged 18 years or more
- •Adequate contraception, if relevant
- •Negative pregnancy test if relevant
- •Written Informed consent
- •Ability to participate to a clinical trial and adhere to study procedures
- •Health insurance
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Therapy related MDS (after chemo- or radiotherapy for a previous neoplasm or immune disorder)
- •Patients with a planned allogeneic bone marrow transplantation
- •Creatininemia >1.5 upper normal value or estimated Ccr less than 30ml/mn
- •ALAT and ASAT >2.5 upper normal value
- •Bilirubin >2N, except unconjugated hyperbilirubinemia due to dyserythropoiesis
- •Heart failure NYHA > II
- •Known allergy to mannitol
- •Other tumor, unstable for the last three years, except in situ uterine carcinoma or basal skin tumor
- •Life expectancy less than 3 months
研究者
相似试验
进行中（未招募）
1 期
ordic multicenter phase II study: Treatment of patients with Acute Myeloid Leukemia (AML) with AZACITIDINE and reduced dose of VENETOCLAX (including laboratory research for improvement of AML treatment).Acute myeloid leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2020-005461-14-DKRigshospitalet117
进行中（未招募）
1 期
ordic multicenter phase II study: Treatment of patients with Acute Myeloid Leukemia (AML) with AZACITIDINE and reduced dose of VENETOCLAX (including laboratory research for improvement of AML treatment).Acute myeloid leukemia (AML)MedDRA version: 21.0Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2020-005461-14-FIRigshospitalet117
进行中（未招募）
1 期
Azacitidine in children with MDS or JMMEUCTR2010-022235-10-DEErasmus MC65
进行中（未招募）
不适用
Azacitidine in children with MDS or JMMAdvanced Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML)MedDRA version: 15.1Level: LLTClassification code 10054439Term: Juvenile chronic myelomonocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 15.1Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 100000004864EUCTR2010-022235-10-ITErasmus MC65
进行中（未招募）
1 期
Azacitidine in children with MDS or JMMAdvanced Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leukemia (JMML)MedDRA version: 17.1Level: LLTClassification code 10054439Term: Juvenile chronic myelomonocytic leukemiaSystem Organ Class: 100000004864MedDRA version: 17.1Level: LLTClassification code 10068361Term: MDSSystem Organ Class: 100000004864EUCTR2010-022235-10-ESErasmus MC5